Modality
Peptide
MOA
TNFi
Target
CD3
Pathway
mTOR
RSVGAEndometrial Ca
Development Pipeline
Preclinical
~Sep 2016
→ ~Dec 2017
Phase 1
~Mar 2018
→ ~Jun 2019
Phase 2
Sep 2019
→ Feb 2028
Phase 2Current
NCT05752003
2,843 pts·Endometrial Ca
2019-09→2028-02·Not yet recruiting
2,843 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-182mo awayOrphan Drug· Endometrial Ca
2028-02-061.9y awayPh3 Readout· Endometrial Ca
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P2/3
Not yet…
Catalysts
Orphan Drug
2026-05-18 · 2mo away
Endometrial Ca
Ph3 Readout
2028-02-06 · 1.9y away
Endometrial Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05752003 | Phase 2/3 | Endometrial Ca | Not yet recr... | 2843 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| 369-789 | Hansoh Pharma | Phase 3 | PI3Kα | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 | |
| MDG-4513 | Madrigal Pharma | Phase 1/2 | CD3 |